Sarcoma Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR (2024 - 2029) | 8.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Sarcoma Drugs Market Analysis
The Sarcoma Drugs Market is expected to register a CAGR of 8.5% during the forecast period.
- The growing patient assistance programs, new product launches, and increased focus on R&D by pharmaceutical companies are contributing to the sarcoma drugs market's growth.
- Research studies have led to the development of innovative sarcoma drugs, which are expected to fuel market growth. For instance, in May 2022, researchers at Washington University School of Medicine in St. Louis developed an investigational drug that triggered cell death for synovial sarcoma, a rare tumor of soft tissues. They planned a phase 1 clinical trial to investigate its safety and effectiveness in patients who had synovial sarcoma that had spread beyond the original tumor site. Such developments are expected to expand the treatment options for various types of sarcomas, further propelling market growth.
- The growing burden of sarcoma is expected to increase demand for effective treatment with sarcoma drugs and is likely to contribute to market growth. For instance, according to the Canadian Cancer Society updated in 2023, 1,700 Canadians were diagnosed with soft tissue sarcoma (including cancer of the heart). Thus, the high burden of sarcoma is expected to contribute to market growth.
- Market players' strategic initiatives, such as product approvals, launches, innovation in products, and partnerships, are also driving the growth of the sarcoma drugs market. For instance, in September 2022, Radiopharm Theranostics entered an exclusive licensing agreement with the University of California Los Angeles (UCLA) Technology Development Group to develop DUNP19 as antibody-drug conjugates within radiotherapy.
- DUNP19 is a first-in-class therapy with dual-action tumor targeting designed to find, internalize, and destroy cancer cells and cells in the tumor microenvironment. Since current treatment options for osteosarcoma include surgery and chemotherapy, such partnerships for the development of targeted therapy for osteosarcoma are expected to expand the treatment options for patients, further driving market growth during the forecast period.
- Additionally, in September 2022, the US Food and Drug Administration (US FDA) granted orphan drug designation (ODD) to Avacta Group's lead drug candidate, AVA6000, to treat soft tissue sarcoma. AVA6000 is a generic chemotherapy doxorubicin. AVA6000 is undergoing a Phase I clinical trial to evaluate its safety and pharmacokinetics in treating patients with various types of cancers, including soft tissue sarcoma.
- In summary, the increasing R&D activities and product launches by pharmaceutical companies are expected to drive growth in the sarcoma drugs market. However, the high cost of treatment and reimbursement issues may restrain market growth during the forecast period.
Sarcoma Drugs Market Trends
Immunotherapy is Expected to Register Significant Growth Over the Forecast Period
- Immunotherapy is a type of treatment that uses medications to help a person's immune system recognize and destroy cancer cells more effectively. The segment is expected to witness significant growth during the forecast period due to the increasing number of clinical trials and the approval of immunotherapy drugs for sarcomas.
- Numerous clinical trials are being conducted to study the effectiveness of immunotherapy for different types of sarcomas, either independently or in combination with other treatments. Phase 1 of the trial was expected to be completed by January 2024. According to clinicaltrials.gov, as of January 2023, there are 44 active trials for immunotherapy for sarcomas, with the status of recruiting, active, not recruiting, and enrolling by invitation studies. Thus, the increasing number of clinical trials studying immunotherapy for treating sarcomas is expected to drive the growth of this segment.
- Furthermore, strategic initiatives taken by market players, such as product launches, approvals, and partnerships, are expected to boost the segment's growth. For instance, in December 2022, the US Food and Drug Administration (US FDA) approved atezolizumab or Tecentriq, manufactured by Roche's Genentech Inc., for adult and pediatric patients aged two years and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). This cancer immunotherapy can reactivate the immune system, enabling it to identify cancer cells in the body. Such approvals of advanced immunotherapy drugs for sarcomas are expected to fuel the growth of the segment during the forecast period.
- In conclusion, the high number of clinical trials for immunotherapy and the increasing approvals of immunotherapy drugs are anticipated to propel the growth of this segment during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
- North America is expected to hold a significant share of the sarcoma drugs market. This is primarily due to several factors, such as the high burden of sarcomas in the region, increasing research and development activities by market players to develop innovative sarcoma drugs, rising patient assistance programs, better healthcare infrastructure, and the strong presence of industry players.
- According to the American Cancer Society's 2024 update, about 13,590 new soft tissue sarcomas are expected to be diagnosed (7,700 in males and 5,890 in females). Thus, the high burden of sarcoma is expected to contribute to market growth.
- The growing approvals and launches of several drugs for sarcoma, as well as collaborations, are boosting segment growth. For instance, in February 2024, QBiotics Group Limited announced that the FDA had granted an orphan drug designation to the novel small molecule agent, tigilanol tailgate (Stelfonta), as a potential therapeutic option for the treatment of patients with soft tissue sarcoma.
- In December 2022, Genentech, a member of Roche Group, announced that the US Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the treatment of adult and pediatric patients aged two years and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). ASPS is a rare, insidious soft tissue sarcoma most common in younger people that is often advanced at diagnosis, can spread slowly but inexorably over decades, and often returns following surgery. This approval brings new hope for children, adults, and their families affected by advanced alveolar soft part sarcoma, who historically have had very limited treatment options.
- Therefore, the North American market for sarcoma drugs is expected to grow significantly due to the high burden of sarcomas and increasing R&D activities in the region, leading to the development of innovative sarcoma therapies.
Sarcoma Drugs Industry Overview
The sarcoma drugs market is characterized by consolidation and is dominated by a few key players. Currently, all of these companies hold significant market shares. Some of the major market players include Eisai Co. Ltd, Johnson & Johnson Inc., Bayer AG, Pfizer Inc., Fresenius Kabi AG, Novartis AG, Ipsen (Epizyme Inc.), Radiopharm Theranostics, F. Hoffmann-La Roche AG, and Eli Lilly and Company.
Sarcoma Drugs Market Leaders
-
Eisai Co., Ltd.
-
Bayer AG
-
Pfizer Inc.
-
Novartis AG
-
Johnson and Johnson Inc.
*Disclaimer: Major Players sorted in no particular order
Sarcoma Drugs Market News
- February 2024: The FDA expedited its review of afamitresgene autoleucel (afami-cel), a novel engineered T-cell therapy for treating patients with advanced synovial sarcoma.
- September 2023: Moleculin Biotech Inc. announced the completion of enrollment in the Phase 2 portion of the company's US Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
Sarcoma Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Patient Assistance Progrms (PAPS)
4.2.2 Increasing New Drug Launches for Sarcoma
4.2.3 Rising Focus of Pharmaceutical Companies on R&D
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Reimbursement Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.1.3 Immuno Therapy
5.1.4 Other Treatment Types
5.2 By Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eisai Co. Ltd
6.1.2 Johnson and Johnson Inc.
6.1.3 Bayer AG
6.1.4 Pfizer Inc.
6.1.5 Fresenius Kabi AG
6.1.6 Novartis AG
6.1.7 Ipsen (Epizyme Inc.)
6.1.8 Radiopharm Theranostics
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Pfizer Inc.
6.1.11 Eli Lilly and Company
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Sarcoma Drugs Industry Segmentation
As per the scope of the report, sarcoma is a type of cancer that can occur in various parts of the body, and it is a term used for the large group of cancers that start in the bone and soft tissues.
The sarcoma drugs market is segmented by type of treatment and geography. By type of treatment, the market is segmented as chemotherapy, targeted therapy, immunotherapy, and other treatment types. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The report offers the value (USD) for the above segments.
| By Treatment Type | |
| Chemotherapy | |
| Targeted Therapy | |
| Immuno Therapy | |
| Other Treatment Types |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Sarcoma Drugs Market Research FAQs
What is the current Sarcoma Drugs Market size?
The Sarcoma Drugs Market is projected to register a CAGR of 8.5% during the forecast period (2024-2029)
Who are the key players in Sarcoma Drugs Market?
Eisai Co., Ltd., Bayer AG, Pfizer Inc., Novartis AG and Johnson and Johnson Inc. are the major companies operating in the Sarcoma Drugs Market.
Which is the fastest growing region in Sarcoma Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Sarcoma Drugs Market?
In 2024, the North America accounts for the largest market share in Sarcoma Drugs Market.
What years does this Sarcoma Drugs Market cover?
The report covers the Sarcoma Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Sarcoma Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Sarcoma Drugs Industry Report
Statistics for the 2024 Sarcoma Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Sarcoma Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Sarcoma Drugs Market Report Snapshots
